An overview of glycemic goals and medications used to manage type 2 diabetes

Nutrition Today

Volumn 50, Issue 1, 2015, Pages 40-48

  Grams, Mary Kathleen ^a   Dinsmore, Suzanne ^b   Goldman Levine, Jennifer ^b   Rebecca Couris, R ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923233200     PISSN: 0029666X     EISSN: 15389839     Source Type: Journal    
DOI: 10.1097/NT.0000000000000074     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2. Centers for Disease Control and Prevention. Diabetes Success and Opportunities for Population-Based Prevention and Control, At a Glance, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. American Diabetes Association. Standards of Medical Care in DiabetesV2014. Diabetes Care. 2013; 37 (Supplement-1): S14-S80.
4. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest. 1976; 57 (6): 1652-1659.
5. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008; 26 (2): 77-82.
6. Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetesVUnited States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep. 2010; 59 (42): 1361-1366.
7. StuartAN. The fundamentals of diabetesmanagement. Nutr Today. 2012; 47 (2): 75-78.
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an AmericanAssociation ofClinical Endocrinologists/AmericanCollege of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr PractOff JAmColl Endocrinol Am Assoc Clin Endocrinol. 2009; 15 (6): 540-559.
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32 (1): 193-203.
10. Management of DiabetesMellitusUpdateWorkingGroup.VA/DoD Clinical PracticeGuideline for theManagement ofDiabetesMellitus. Version 4.0.Washington, DC: Veterans Health Administration and Department of Defense; 2010.
11. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary andSecondaryCare (Update).London: Royal College of Physicians; 2008.
12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the EuropeanAssociation for the Study ofDiabetes (EASD). Diabetes Care. 2012; 35 (6): 1364-1379.
13. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo SeguraM, Roquéi Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. In: The Cochrane CollaborationSaenz A, eds. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2005. http://doi.wiley.com/10.1002/14651858.CD002966 .pub3. Accessed January 14, 2014.
14. De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340: c2181.
15. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosiswithmetformin use in type 2 diabetes mellitus. Cochrane Database Syst RevOnline. 2010; 4: CD002967.
16. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005; 65 (3): 385-411.
17. FDADrug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines [Internet]. Silver Spring, MD: US Food and Drug Administration. 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed January 23, 2014.
18. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ Can Med Assoc J. 2012; 184 (12): E675-E683.
19. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ Can Med Assoc J. 2009; 180 (1): 32-39.
20. Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med. 2010; 8 (6): 542-549.
21. Dicker D. DPP-4 Inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011; 34 (supplement-2): S276-S278.
22. Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012; 13 (10): 1451-1467.
23. Tanzeum (R) [package insert].Wilmington, DE: GlaxoSmithKline LLC; 2014.
24. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetesmellitus. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2013; 4 (2): 195-220.
25. Stenlöf K, Cefalu WT, Kim K-A, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014; 30 (2): 163-75. doi: 10.1185/03007995.2013.850066. Epub 2013 Oct 28.
26. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozinmonotherapy in subjects with type 2 diabetesmellitus inadequately controlledwith diet and exercise. Diabetes Obes Metab. 2013; 15 (4): 372-382.
27. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patientswith inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care. 2010; 33 (10): 2217-2224.
28. Welchol (R) [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2013.
29. OoiCP, Loke SC. Colesevelamfor type 2 diabetesmellitus. Cochrane Database Syst Rev Online. 2012; 12: CD009361.
30. Cycloset (R) [package insert], San Diego, CA: Santarus Inc, 2010.
31. DeFronzo RA.Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011; 34 (4): 789-794.
32. Maria Rotella C, Pala L, Mannucci E. Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab. 2013; 11 (3): 137-144.
33. Clinical Pharmacology [database online], Tampa, FL: Elsevier/Gold Standard, Inc, 2014. http://www.clinicalpharmacology.com.